https://www.enterair.pl/slot-gacor/

БАКТЕРИАЛЬНАЯ ТРАНСЛОКАЦИЯ В ПАТОГЕНЕЗЕ ОСЛОЖНЕНИЙ ЦИРРОЗА ПЕЧЕНИ

  • Д. И. Гавриленко Республиканский научно-практический центр радиационной медицины и экологии человека, Гомель, Беларусь http://orcid.org/0000-0001-7496-6164
  • Н. Н. Силивончик Белорусская медицинская академия последипломного образования, Минск, Беларусь http://orcid.org/0000-0002-6167-9737
Ключевые слова: цирроз печени, транслокация, липополисахарид, бактериальная ДНК

Аннотация

Введение. Понимание физиологии взаимодействия бактерий кишки и организма хозяина, особенностей бактериальной транслокации на начальных стадиях и в случае прогрессирующего ЦП подчеркивает важность подходов, минимизирующих миграцию микроорганизмов и их компонентов из просвета кишки. Цель исследования – краткий обзор публикаций, освещающих проблему бактериальной кишечной транслокации – основного механизма развития бактериальных инфекций и провоспалительного статуса при циррозе печени. Материал и методы. Выполнялись изучение и анализ англо- и русскоязычных статей с глубиной поиска 30 лет, содержащихся в базах данных PubMed, Cochrane Collaboration, UpToDate. Ключевыми словами были: «транслокация кишечной микрофлоры», «бактериальная транслокация», «маркеры транслокации». Результаты. Рассмотрены современные представления об изменении кишечного барьера, систем врожденного и адаптивного иммунитета при заболеваниях печени. Приведены данные о возможности и значимости обнаружения бактериальной транслокации. Обсуждаются современные методы, используемые для анализа микробиома кишечника, а также некоторые области для будущих исследований. Заключение. Для изучения бактериальной транслокации при циррозе печени необходимы валидированные маркер/маркеры.

Литература

Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol. 2016;8(6):307-321. https://doi.org/10.4254/wjh.v8.i6.307.

Bartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7(3):309-319. https://doi.org/10.1080/21505594.2016.1141162.

Wong F, Bernardi M, Balk R, Cristman B, Moreau R, Garsia-Tsao G, Path D, Soriano G, Hoefs J, Navasa M. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut. 2005;54(5):718-725. https://doi.org/10.1136/gut.2004.038679.

Konturek PC, Harsch IA, Konturek K, Schink M, Konturek K, Neurath MF, Zopf Y. Gut-Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel). 2018;6(3):79. https://doi.org/10.3390/medsci6030079.

Oliveira JDC, Carrera E, Petry RC, Deutschendorf C, Mantovani A, Barcelos STA, Cassales S, Schacher FC, Lopes AB, Alvares-Da-Silva MR. High prevalence of multidrug resistant bacteria in cirrhotic patients with spontaneous bacterial peritonitis: is it time to change the standard antimicrobial approach? Can JGastroenterol Hepatol. 2019:6963910. https://doi.org/10.1155/2019/6963910.

Fernández J, Bert F, Nicolas-Chanoine MH. The challenges of multi-drug-resistance in hepatology. J Hepatol. 2016;65(5):1043-1054. https://doi.org/10.1016/j.jhep.2016.08.006.

Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d’Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, et al. Effects of long-term norfloxacin therapy in patients with advanced cirrhosis. Gastroenterology. 2018;155(6):1816-1827.e9. https://doi.org/10.1053/j.gastro.2018.08.026.

Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Ginès P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818-824. https://doi.org/10.1053/j.gastro.2007.06.065.

Gavrilenko DI, Silivonchik NN. Struktura i antibiotikorezistentnost vozbuditelej infekcij u gospitalizirovannyh pacientov s dekompensirovannym cirrozom pecheni [The structure and antibiotic resistance of infectious pathogens in hospitalized patients with decompensated cirrhosis]. Klinicheskaya infektologiya i parazitologiya [Clinical infectology and parasitology]. 2015;2:34-45. (Russian).

Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859-904. https://doi.org/10.1152/physrev.00045.2009.

Brann OS. Infectious complications of cirrhosis. Curr Gastroenterol Rep. 2001;3(4):285-292. https://doi.org/10.1007/s11894-001-0051-2.

Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol.2011;49(4):406-413. https://doi.org/10.3109/13693786.2010.535030.

Gavrilenko DI. Ostryj miliarnyj tuberkulez u pacientki s cirrozom pecheni [Acute miliary tuberculosis in patients with liver cirrhosis]. Lechebnoe delo [General Medicine]. 2015;2:81-83. (Russian).

Janeway CA, Medzhitov Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. https://doi.org/10.1146/annurev.immunol.20.083001.084359.

Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010;2010:192543. https://doi.org/10.1155/2010/192543.

Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int. 2010;4(4):659-672. https://doi.org/10.1007/s12072-010-9219-x.

De Creus A, Abe M, Lau AH, Hackstein H, Raimondi G, Thomson AW. Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. J Immunol. 2005;174(4):2037-2045. https://doi.org/10.4049/jimmunol.174.4.2037.

Shu SA, Lian ZX, Chuang YH, Yang GX, Moritoki Y, Comstock SS, Zhong RQ, Ansari AA, Liu YJ, Gershwin ME. The role of CD11c(+) hepatic dendritic cells in the induction of innate immune responses. Clin Exp Immunol. 2007;149(2):335-343. https://doi.org/10.1111/j.1365-2249.2007.03419.x.

Castellano G, Stasi A, Intini A, Gigante M, Di Palma AM, Divella C, Netti GS, Prattichizzo C, Pontrelli P, Crovace A, Staffieri F, Fiaccadori E, Brienza N, Grandaliano G, Pertosa G, Gesualdo L. Endothelial dysfunction and renal fibrosis in endotoxemia-induced oliguric kidney injury: possible role of LPS-binding protein. Crit Care. 2014;18(5):520. https://doi.org/10.1186/s13054-014-0520-2.

Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology. 2010;51(4):1327-1333. https://doi.org/10.1002/hep.23440.

Francés R, Muñoz C, Zapater P, Uceda F, Gascón I, Pascual S, Pérez-Mateo M, Such J. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut. 2004;53(6):860-864. https://doi.org/10.1136/gut.2003.027425.

Bruns T, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl J, Schölmerich J, Wiest R, Stallmach A. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int. 2012;32(2):223-230. https://doi.org/10.1111/j.1478-3231.2011.02561.x.

Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-1290. https://doi.org/10.1056/NEJMra0809139.

Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C, Chen PC, Wu CS. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43(4):673-681. https://doi.org/10.1002/hep.21101.

Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26-42. https://doi.org/10.1055/s-2008-1040319.

Fukui H. How leaky gut and endotoxemia induce bacterial infection in cirrhosis and gastrointestinal hemorrhage? J Gastroenterol Hepatol. 2011;26(3):423-425. https://doi.org/10.1111/j.1440-1746.2011.06668.x.

Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs A.K. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998;27(5):1207-1212. https://doi.org/10.1002/hep.510270504.

Cervoni JP, Amorós À, Bañares R, Luis Montero J, Soriano G, Weil D, Moreau R, Pavesi M, Thévenot T, Di Martino V; EASL-CLIF Consortium. Prognostic value of C-reactive protein in cirrhosis: external validation from the CANONIC cohort. Eur J Gastroenterol Hepatol. 2016;28(9):1028-1034. https://doi.org/10.1097/MEG.0000000000000676.

Lazzarotto C, Ronsoni MF, Fayad L, Nogueira CL, Bazzo ML, Narciso-Schiavon JL, de Lucca Schiavon L, Dantas-Corrêa EB. Acute phase proteins for the diagnosis of bacterial infection and prediction of mortality in acute complications of cirrhosis. Ann Hepatol. 2013;12(4):599-607.

Kadam N, Acharya S, Shukla S, Gupta K. Ascitic Fluid High Sensitive C-Reactive Protein (hs-CRP). A Prognostic Marker in Cirrhosis with Spontaneous Bacterial Peritonitis. J Clin Diagn Res. 2016;10(4):20-24. https://doi.org/10.7860/JCDR/2016/17931.7610.

Lesińska M, Hartleb M, Gutkowski K, Nowakowska-Duława E. Procalcitonin and macrophage inflammatory protein-1 beta (MIP-1β) in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Adv Med Sci. 2014;59(1):52-56. https://doi.org/10.1016/j.ad-vms.2013.07.006.

Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med. 2005;146(6):347-351. https://doi.org/10.1016/j.lab.2005.08.005.

Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, Monnet E, Di Martino V. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol. 2012;56(6):1299-1304. https://doi.org/10.1016/j.jhep.2011.12.030.

Leventhal JS, Schröppel B. Toll-like receptors in transplantation: sensing and reacting to injury. Kidney Int.2012;81(9):826-832. https://doi.org/10.1038/ki.2011.498.

Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147(6):1327-1337. https://doi.org/10.1053/j.gastro.2014.08.031.

Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet. 2004;363(9421):1608-1610. https://doi.org/10.1016/S0140-6736(04)16206-5.

Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911-921. https://doi.org/10.1016/j.jhep.2012.12.011.

Ishikura H, Nishida T, Murai A, Nakamura Y, Irie Y, Tanaka J, Umemura T. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care. 2014;18(1):R19. https://doi.org/10.1186/cc13700.

Papp M, Tornai T, Vitalis Z, Tornai I, Tornai D, Dinya T, Sumegi A, Antal-Szalmas P. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol. 2016;22(41):9172-9185. https://doi.org/10.3748/wjg.v22.i41.9172.

Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272-1284. https://doi.org/10.1016/j.jhep.2015.07.004.

Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52(6):2044-2052. https://doi.org/10.1002/hep.23918.

Krohn S, Böhm S, Engelmann C, Hartmann J, Brodzinski A, Chatzinotas A, Zeller K, Prywerek D, Fetzer I, Berg T. Application of qualitative and quantitative real-time PCR, direct sequencing, and terminal restriction fragment length polymorphism analysis for detection and identification of polymicrobial 16S rRNA genes in ascites. J Clin Microbiol. 2014;52(5):1754-1757. https://doi.org/10.1128/JCM.00552-14.

Francés R, Zapater P, González-Navajas JM, Muñoz C, Caño R, Moreu R, Pascual S, Bellot P, Pérez-Mateo M, Such J. Bacterial DNA in patients with cirrhosis and non-infected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology. 2008;47(3):978-985. https://doi.org/10.1002/hep.22083.

Engelmann C, Krohn S, Prywerek D, Hartmann J, Herber A, Boehlig A, Zeller K, Boehm S, Berg T. Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. Eur J Gastroenterol Hepatol. 2016;28(11):1285-1292. https://doi.org/10.1097/MEG.0000000000000712.

Vinnitskaya EV. Spontannyj bakterialnyj peritonit: novye podhody k diagnostike pri alkogolnom cirroze pecheni [Spontaneous bacterial peritonitis: new approaches to diagnosis in alcoholic liver cirrhosis]. Eksperimentalnaya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2008;4:97-102. (Russian).

Bruns T, Reuken PA, Stengel S, Gerber L, Appenrodt B, Schade JH, Lammert F, Zeuzem S, Stallmach A. The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection. Liver Int. 2016;36(8):1133-1142. https://doi.org/10.1111/liv.13095.

Kopcinovic L, Culej J, Jokic A, Bozovic M, Kocijan I. Laboratory testing of extravascular body fluids: National recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Part I - Serous fluids. Biochem Med (Zagreb). 2020;30(1):010502. https://doi.org/10.11613/BM.2020.010502.

Lutz P, Pfarr K, Nischalke HD, Krämer B, Goeser F, Glässner A, Wolter F, Kokordelis P, Nattermann J, Sauerbruch T, Hoerauf A, Strassburg CP, Spengler U. The ratio of calprotectin to total protein as a diagnostic and prognostic marker for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. Clin Chem Lab Med. 2015;53(12):2031-2039. https://doi.org/10.1515/cclm-2015-0284.

Fernandes SR, Santos P, Fatela N, Baldaia C, Tato Marinho R, Proença H, Ramalho F, Velosa J. Ascitic Calprotectin is a Novel and Accurate Marker for Spontaneous Bacterial Peritonitis. J Clin Lab Anal. 2016;30(6):1139-1145. https://doi.org/10.1002/jcla.21994.

Kirkovskij VV, Dzjadzko AM, Gapanovich VN, Priluckij PS, Rjabceva TV. Izmenenie srednego arterialnogo davlenija i obshhego perifericheskogo soprotivlenija pri provedenii LPS-sorbcii u pacientov s septicheskim shokom v posleoperacionnom periode ortotopicheskoj transplantacii pecheni [Changing average blood pressure and general peripheral resistance under LPS sorption in patients with septic shock in postoperative period after orthotopic liver transplantation]. Zdravoohranenie [Healthcare]. 2019;5:51-55. (Russian)

Опубликован
2021-01-13
Как цитировать
1.
Гавриленко ДИ, Силивончик НН. БАКТЕРИАЛЬНАЯ ТРАНСЛОКАЦИЯ В ПАТОГЕНЕЗЕ ОСЛОЖНЕНИЙ ЦИРРОЗА ПЕЧЕНИ. journalHandG [Интернет]. 13 январь 2021 г. [цитируется по 22 декабрь 2024 г.];4(2):143-50. доступно на: http://hepatogastro.grsmu.by/index.php/journalHandG/article/view/154

Наиболее читаемые статьи этого автора (авторов)

https://stok.bte.co.id/pg/ https://coverage.bte.co.id/public/play/ https://lapor.bte.co.id/rungkat/ https://itj.jakartamrt.co.id/data/ https://dev.idcomm.id/wp-includes/IXR/slot-gacor/